

## New light on prostate cancer

Industry session by STEBA BIOTECH

**Sunday, 26 March**  
**17:45 - 19:15**

**Location:** Room 7, Capital suite (level 3)

17:45 - 17:50

**Welcome and introduction**

17:50 - 18:05

**Should we treat Gleason 6 prostate cancer?**

M. Wirth, Dresden (DE)

18:05 - 18:20

**Data on phase III pivotal trials of TOOKAD® Soluble vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer**

M. Emberton, London (GB)

18:20 - 18:35

**How will focal therapy change current treatment of localized prostate cancer**

N. Mottet, Saint-Étienne (FR)

18:35 - 18:50

**Technical aspect of VTP Surgery**

A.R. Azzouzi, Angers (FR)

18:50 - 19:05

**Introduction into the mechanism of action of vascular-targeted photodynamic therapy - TOOKAD® Soluble**

A. Scherz, Rehovot (IL)

19:05 - 19:15

**Question and answers**